 |
|
Four months of rifampicin monotherapy for latent tuberculosis infection in children
Chi Eun Oh, Dick Menzies
Clin Exp Pediatr. 2022;65(5):214-221. Published online 2021 Oct 29 DOI: https://doi.org/10.3345/cep.2021.01186
|
|
Citations to this article as recorded by
 Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion
Yejin Kim, Kil Seong Bae, Ui Yoon Choi, Seung Beom Han, Jong-Hyun Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef Telemedicine as a tool to prevent multi-drug resistant tuberculosis in poor resource settings: Lessons from Nigeria
Kikelomo S. Olowoyo, Deborah T. Esan, Benedict T. Adeyanju, David B. Olawade, Babatunji E. Oyinloye, Paul Olowoyo
Journal of Clinical Tuberculosis and Other Mycobac.2024; 35: 100423. CrossRef Pulmonary Tuberculosis in Children: A Forgotten Disease?
Umberto Pelosi, Roberta Pintus, Salvatore Savasta, Vassilios Fanos
Microorganisms.2023; 11(7): 1722. CrossRef Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen Mycobacterium tuberculosis
Giuseppe Mancuso, Angelina Midiri, Silvia De Gaetano, Elena Ponzo, Carmelo Biondo
Microorganisms.2023; 11(9): 2277. CrossRef Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Véronique A. Dartois, Eric J. Rubin
Nature Reviews Microbiology.2022; 20(11): 685. CrossRef Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger
Elena G. Salina, Vadim Makarov
Microorganisms.2022; 10(12): 2334. CrossRef
|